News

Discover all the latest news from Bioprojet: events, updates, innovations… Stay informed about the latest scientific advances and new developments in our therapeutic areas.

#BIONEWS

Mai 2023

Bioprojet participates in the Congress of the French Society of Pediatrics

On May 31th to June 2nd 2023 will take place the national congress “Congrès de la Société Française de Pédiatrie”. Meet us at the Parc Chanot, in Marseille, in France.

READ

Avr 2023

Bioprojet participates in the Francophone Congress of Allergology in Paris

On April 25 – 28 2023 will take place the congress “Congrès Francophone d’Allergologie” (CFA). Meet us at the Palais des Congrès Porte Maillot, in Paris.

READ

Avr
2023
Avr
2023
Bioprojet participates in the Francophone Congress of Allergology in Paris

Bioprojet participates in the Francophone Congress of Allergology in Paris

On April 25 – 28 2023 will take place the congress “Congrès Francophone d’Allergologie” (CFA). Meet us at the Palais des Congrès Porte Maillot, in Paris.

READ

Avr
2023
Avr
2023
Organisation of the international congress “Sleep & Breathing” in Prague

Organisation of the international congress “Sleep & Breathing” in Prague

On April 20, 21 and 22, 2023 will take place the international congress “Sleep & Breathing” by the European Respiratory Society (ERS) in partnership with the European Sleep Research Society (ESRS). Meet us in Prague, Czech Republic.

READ

Mar
2023
Mar
2023
Bioprojet participates in the 24th edition of the Journées Interactives de Réalités Pédiatriques

Bioprojet participates in the 24th edition of the Journées Interactives de Réalités Pédiatriques

The 24th edition of JIRP (Journées Interactives de Réalités Pédiatriques) will take place on March 23rd and 24th 2023. See you at the Palais des Congrès in Versailles.

READ

Mar
2023
Mar
2023
Aculys Pharma launches a therapeutic trial for excessive daytime sleepiness (EDS)

Aculys Pharma launches a therapeutic trial for excessive daytime sleepiness (EDS)

The private biopharmaceutical company, Aculys Pharma, is launching a phase III therapeutic trial for excessive daytime sleepiness (EDS). The test patients in this trial have obstructive sleep apnea syndrome (OSA) and complain of EDS. This is manifested by upper airway obstruction, coupled with fatigue, drowsiness and an overall lack of energy. The trial aims to […]

READ

PAGE 8 SUR 7